BridgeBio Pharma Inc [NASDAQ: BBIO] traded at a high on Monday, posting a 15.99 gain after which it closed the day’ session at $33.73.
The results of the trading session contributed to over 10099077 shares changing hands. Over the past one week, the price volatility of BridgeBio Pharma Inc stands at 7.11% while the volatility over the past one month is 4.92%.
The market cap for BBIO stock reached $6.37 billion, with 188.99 million shares outstanding and 147.77 million shares in the current float. Compared to the average trading volume of 1.94M shares, BBIO reached a trading volume of 10099077 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about BridgeBio Pharma Inc [BBIO]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for BBIO shares is $50.36 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on BBIO stock is a recommendation set at 1.29. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Scotiabank have made an estimate for BridgeBio Pharma Inc shares, keeping their opinion on the stock as Sector Outperform, with their previous recommendation back on October 16, 2024. While these analysts kept the previous recommendation, Oppenheimer raised their target price to Perform. The new note on the price target was released on October 03, 2024, representing the official price target for BridgeBio Pharma Inc stock. Previously, the target price had yet another raise to $46, while Piper Sandler analysts kept a Overweight rating on BBIO stock.
The Average True Range (ATR) for BridgeBio Pharma Inc is set at 1.54, with the Price to Sales ratio for BBIO stock in the period of the last 12 months amounting to 29.27.
How has BBIO stock performed recently?
BridgeBio Pharma Inc [BBIO] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 19.95. With this latest performance, BBIO shares gained by 16.15% in over the last four-week period, additionally plugging by 24.37% over the last 6 months – not to mention a drop of -15.46% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BBIO stock in for the last two-week period is set at 75.89, with the RSI for the last a single of trading hit 82.75, and the three-weeks RSI is set at 70.70 for BridgeBio Pharma Inc [BBIO]. The present Moving Average for the last 50 days of trading for this stock 26.68, while it was recorded at 29.87 for the last single week of trading, and 26.62 for the last 200 days.
BridgeBio Pharma Inc [BBIO]: Deeper insight into the fundamentals
BridgeBio Pharma Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 3.19 and a Current Ratio set at 3.19.
Insider trade positions for BridgeBio Pharma Inc [BBIO]
There are presently around $94.12%, or 96.94%% of BBIO stock, in the hands of institutional investors. The top three institutional holders of BBIO stocks are: KOHLBERG KRAVIS ROBERTS & CO. L.P. with ownership of 31.06 million shares, which is approximately 16.5582%. VIKING GLOBAL INVESTORS LP, holding 25.12 million shares of the stock with an approximate value of $$636.31 million in BBIO stocks shares; and VIKING GLOBAL INVESTORS LP, currently with $$356.01 million in BBIO stock with ownership which is approximately 7.4924%.
